Alex Brill mentioned on MSN
If the Supreme Court rules in their favor, it could open the door to reshaping the country’s tax code.
Alex Brill Speaks on Consequences of Proposed PBM Constraints
In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
Patent Thicket Remedies
Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
This Corporate Law Case Could Accidentally Overturn U.S. Taxes
This week, the Supreme Court will hear oral arguments in Moore v. United States, a case that centers on the mandatory repatriation tax (MRT).
Don’t Mix US Tax Administration Policy with the Israel-Hamas Conflict
House lawmakers are expected to vote soon on an emergency supplemental funding bill to provide military support to Israel in its war against Hamas terrorists.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
